Abingworth provides growth capital to companies in life sciences or healthcare businesses seeking expansion capital, acquisition financing, or structured financing for recapitalisations, build-ups and growth buyouts. Abingworth will commit between $20 million and $80 million to a specific growth equity investment either initially or over time depending on the size and timing of the funding requirements of the individual company and its strategy.
Healthcare Services and Information Technology
Abingworth’s healthcare growth investments focus on “first movers” in emerging and niche markets or companies with experienced executives in established sectors leveraging a contrarian view and attractive consolidations economics.
Areas of interest: Providers, Payors, Speciality Services, Software and Related Services.
Abingworth’s life sciences growth investments focus on growing and maturing life sciences companies seeking equity capital for growth and expansion beyond the funding capacity of more traditional venture capital. These companies are likely to have revenues and in many cases operating earnings. They may also be pursuing an expansion strategy through acquisition that may involve partial debt financing.
Areas of interest: Speciality Pharmaceuticals, Medical Products and Devices, Lab Instrumentation and Consumables, among others.
Robert J. Rosenthal, President and CEO of Magellan Biosciences
I’ve had the opportunity to work with many different venture groups over my 20+ years in the life sciences industry, and Abingworth is outstanding. The team has been a tremendous resource to Magellan – opening doors to potential acquisition and strategic partnering opportunities, introducing us to key people in the industry, pitching in with valuable analysis and insight as we work to achieve our aggressive growth goals and take our place as a worldwide leader in clinical diagnostics. I particularly appreciate that in all of our interactions, Abingworth has been forthright about its objectives and has consistently delivered on its promises.